Details for Patent: 8,148,333

Which drugs does patent 8,148,333 protect, and when does it expire?

Patent 8,148,333 protects TYMLOS and is included in one NDA.

This patent has forty-one patent family members in twenty-seven countries.

Summary for Patent: 8,148,333

Title:	Stable composition comprising a PTHrP analogue
Abstract:	The present invention provides a storage-stable composition containing a parathyroid hormone-related protein (PTHrP) analogue and methods of using a PTHrP analogue and the PTHrP compositions described herein to treat osteoporosis, to increase bone mass or to increase bone quality. The composition is storage stable, in sterile form, and in general may be stored at room temperature for at least several weeks to allow convenient parenteral administration to human patients.
Inventor(s):	Dey; Michael J. (Sandbach, GB), Mondoly; Nathalie (Le Chesnay, FR), Rigaud; Benedicte (Oulins, FR), Henderson; Bart (Belmont, MA), Lyttle; C. Richard (Bala Cynwyd, PA)
Assignee:	Radius Health, Inc. (Cambridge, MA) Ipsen Pharma S.A.S. (Boulogne-Billancourt, FR)
Application Number:	12/311,418
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,148,333
Patent Claim Types: see list of patent claims	Composition;

Drugs Protected by US Patent 8,148,333

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Radius	TYMLOS	abaloparatide	SOLUTION;SUBCUTANEOUS	208743-001	Apr 28, 2017		RX	Yes	Yes			Y

Foreign Priority and PCT Information for Patent: 8,148,333

PCT Information
PCT Filed	October 03, 2007	PCT Application Number:	PCT/US2007/021216
PCT Publication Date:	May 29, 2008	PCT Publication Number:	WO2008/063279

International Family Members for US Patent 8,148,333

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2007322334
Brazil	PI0719821
Brazil	PI0722428
Canada	2664734